OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, announced today the appointment of Jamie Grifo, M.D., Ph.D., of the New York University (NYU) Fertility Center and the Division of Reproductive Endocrinology at the NYU School of Medicine, to its Clinical Advisory Board.
“Throughout his career, Dr. Grifo has been at the forefront of bringing the latest innovations in fertility to patients, such as pre-implantation genetic diagnosis,” said Michelle Dipp, Chief Executive Officer, OvaScience. “His research continues to drive major advances in the field and we look forward to his contributions to OvaScience.”
“As more women delay childbearing, which can result in decreased egg quality, there are a growing number of patients seeking fertility treatments that could benefit from new innovations in the field,” said Dr. Grifo. “OvaScience’s EggPC SM technology is unique in that it has the potential to improve egg quality and offer new possibilities for helping women build their own families.”
Dr. Grifo is renowned in reproductive medicine for his technical innovation and leadership. His team pioneered the first successful use of pre-implantation genetic diagnosis (PGD) in the U.S., a technique which has been used in the assisted reproduction of thousands of children worldwide. Dr. Grifo’s research also produced the NYU Vitrification Method, a standard of care at NYU Fertility Center since 2004. Additional research focuses on egg freezing and stem cells.Dr. Grifo is the Program Director of the New York University (NYU) Fertility Center. Since 1995 he has been the Director of the Division of Reproductive Endocrinology at the NYU School of Medicine where he also holds the faculty appointment of Professor of Obstetrics and Gynecology. He received his M.D. and Ph.D. degrees at Case Western Reserve School of Medicine. A member of the American Society for Reproductive Medicine since 1989, Dr. Grifo has served on the Ethics Committee and is past president of the Society for Assisted Reproductive Technologies.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts